Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: Lancet Neurol. 2010 Oct;9(10):978–985. doi: 10.1016/S1474-4422(10)70184-8

Table 2.

SNPs that achieve genome-wide significance (p-value less than 1·52×10−7) based on Cochrane-Armitage trend test of 405 Finnish ALS cases and 497 Finnish controls.

Rank SNP Chr Position Minor
allele		 Major
allele		 Risk
allele		 MAF
Cases		 MAF
Controls		 MAF
CEU		 Odds Ratio
(95% CI)		 p
1 rs3849942 9 27,533,281 A G A 0·295 0·163 0·183 2·16 (1·72 – 2·70) 9·11×10−11
2 rs2814707 9 27,526,397 A G A 0·295 0·163 0·192 2·14 (1·71 – 2·69) 1·18×10−10
3 rs774359 9 27,551,049 C T C 0·298 0·177 0·225 1·98 (1·58 – 2·47) 3·64×10−9
4 rs13048019 21 31,840,165 T C T 0·291 0·169 0·150 2·02 (1·61 – 2·53) 2·58×10−8
5 rs2225389 9 27,399,264 C A C 0·180 0·089 0·100 2·26 (1·70 – 3·00) 2·88×10−8

Chr, chromosome; SNP position is based on the Human Genome Build 36·3; MAF, minor allele frequency; MAF CEU is the frequency of the minor allele of this SNP in the HapMap Caucasian reference population consisting of 60 unrelated individuals (release 23, see www.hapmap.org for further details); 95% CI, 95% confidence interval.